Pfizer Presents Positive Phase 3 Data at 28th Congress of European Academy of Dermatology and Venereology
October 13, 2019
October 13, 2019
NEW YORK, Oct. 13 -- Pfizer, a pharmaceutical company, issued the following news release:
* * *
- Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study- -Findings follow recent positive top-line results for second abrocitinib Phase 3 pivotal study, JADE MONO-2
* * *
Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to se . . .
* * *
- Abrocitinib met all co-primary and secondary endpoints in JADE MONO-1 study- -Findings follow recent positive top-line results for second abrocitinib Phase 3 pivotal study, JADE MONO-2
* * *
Pfizer Inc. (NYSE: PFE) announced today complete results from a Phase 3, 12-week, pivotal study (JADE MONO-1) in patients aged 12 and older with moderate to se . . .